GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Piotroski F-Score

Taisho Pharmaceutical Holdings Co (TSE:4581) Piotroski F-Score : 6 (As of Apr. 29, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Taisho Pharmaceutical Holdings Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Taisho Pharmaceutical Holdings Co's Piotroski F-Score or its related term are showing as below:

TSE:4581' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Taisho Pharmaceutical Holdings Co was 8. The lowest was 2. And the median was 6.


Taisho Pharmaceutical Holdings Co Piotroski F-Score Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Piotroski F-Score Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 5.00 4.00 6.00

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.00 - - -

Competitive Comparison of Taisho Pharmaceutical Holdings Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was 円18,997 Mil.
Cash Flow from Operations was 円40,972 Mil.
Revenue was 円301,381 Mil.
Gross Profit was 円177,850 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was (888159 + 941490) / 2 = 円914824.5 Mil.
Total Assets at the begining of this year (Mar22) was 円888,159 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.
Total Current Assets was 円375,880 Mil.
Total Current Liabilities was 円73,778 Mil.
Net Income was 円13,122 Mil.

Revenue was 円268,203 Mil.
Gross Profit was 円163,831 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was (876923 + 888159) / 2 = 円882541 Mil.
Total Assets at the begining of last year (Mar21) was 円876,923 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.
Total Current Assets was 円378,864 Mil.
Total Current Liabilities was 円62,277 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Taisho Pharmaceutical Holdings Co's current Net Income (TTM) was 18,997. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Taisho Pharmaceutical Holdings Co's current Cash Flow from Operations (TTM) was 40,972. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=18997/888159
=0.02138919

ROA (Last Year)=Net Income/Total Assets (Mar21)
=13122/876923
=0.01496369

Taisho Pharmaceutical Holdings Co's return on assets of this year was 0.02138919. Taisho Pharmaceutical Holdings Co's return on assets of last year was 0.01496369. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Taisho Pharmaceutical Holdings Co's current Net Income (TTM) was 18,997. Taisho Pharmaceutical Holdings Co's current Cash Flow from Operations (TTM) was 40,972. ==> 40,972 > 18,997 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=0/914824.5
=0

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=0/882541
=0

Taisho Pharmaceutical Holdings Co's gearing of this year was 0. Taisho Pharmaceutical Holdings Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=375880/73778
=5.09474369

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=378864/62277
=6.08353004

Taisho Pharmaceutical Holdings Co's current ratio of this year was 5.09474369. Taisho Pharmaceutical Holdings Co's current ratio of last year was 6.08353004. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Taisho Pharmaceutical Holdings Co's number of shares in issue this year was 82.085. Taisho Pharmaceutical Holdings Co's number of shares in issue last year was 81.539. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=177850/301381
=0.59011683

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=163831/268203
=0.61084701

Taisho Pharmaceutical Holdings Co's gross margin of this year was 0.59011683. Taisho Pharmaceutical Holdings Co's gross margin of last year was 0.61084701. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=301381/888159
=0.33933226

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=268203/876923
=0.30584555

Taisho Pharmaceutical Holdings Co's asset turnover of this year was 0.33933226. Taisho Pharmaceutical Holdings Co's asset turnover of last year was 0.30584555. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Taisho Pharmaceutical Holdings Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Taisho Pharmaceutical Holdings Co  (TSE:4581) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Taisho Pharmaceutical Holdings Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines